Comparative Pharmacology
Head-to-head clinical analysis: FEMCON FE versus NORLESTRIN 28 1 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEMCON FE versus NORLESTRIN 28 1 50.
FEMCON FE vs NORLESTRIN 28 1/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norethindrone and ethinyl estradiol. Inhibits ovulation via suppression of gonadotropins (FSH, LH); increases cervical mucus viscosity, impairing sperm penetration; alters endometrial receptivity.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release via negative feedback on pituitary, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
One tablet (norethindrone 0.5 mg + ethinyl estradiol 35 mcg) orally once daily for 28 days.
One tablet orally once daily, each containing norethindrone 1 mg and ethinyl estradiol 50 mcg.
None Documented
None Documented
The terminal elimination half-life of ethinyl estradiol is 13-18 hours; for norethindrone, it is 7-12 hours. Both allow once-daily dosing for contraceptive efficacy.
Norethindrone: 8 hours; ethinyl estradiol: 12-15 hours; steady state achieved within 5-10 days.
Renal excretion accounts for approximately 40-60% of the dose as metabolites; fecal excretion is about 20-30% via bile. Unchanged drug excretion is minimal.
Norethindrone: 40% renal, 60% fecal; ethinyl estradiol: 40% renal, 60% fecal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive